Well, well, well, @hottod. something tells me that you spotted the wee major discrepancy across the two latest presentations. The big question being (as you raised) is tumour immunosuppression being addressed and by CellPryme-M or A or both?
CellPryme Preso June 8:-
PTX Preso Aug 23:-
Lol.... typo, inadvertent omission or intentional early alert to the market?
I'm more perplexed by that than the complexity of tumor immunosuppression!!! How can that be? Oh, the joys of company disclosures!
What's funny is that when I saw the first slide at the time of its release, my thought was "There's a lot of blanks under CellPryme-M but OmniCAR addresses all the issues and challenges of CarT, so its not a biggie if CellPryme doesn't address them all also. But why would the co. present them side by side like that unless CP does address them all?" I still consider that some may not be applicable to CP... but now, maybe not.
If CellPryme-M and/or A address the issue of immune cell suppression and the microenvironment, then surely this issues of escape, heterogeneity and safety are then also addressed.
